# Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

> **NCT05893693** · NA · UNKNOWN · sponsor: **Aibin Liang，MD，Ph.D.** · enrollment: 12 (estimated)

## Conditions studied

- Relapsed and/or Refractory Multiple Myeloma
- Plasma Cell Leukemia in Relapse

## Interventions

- **OTHER:** Biological

## Key facts

- **NCT ID:** NCT05893693
- **Lead sponsor:** Aibin Liang，MD，Ph.D.
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-12
- **Primary completion:** 2026-01-01
- **Final completion:** 2026-01-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2023-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05893693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05893693, "Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05893693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*